{"nctId":"NCT04497987","briefTitle":"A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff","startDateStruct":{"date":"2020-08-02","type":"ACTUAL"},"conditions":["COVID-19","SARS-CoV2"],"count":1180,"armGroups":[{"label":"Bamlanivimab (Part 1)","type":"EXPERIMENTAL","interventionNames":["Drug: Bamlanivimab"]},{"label":"Placebo (Part 1)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Bamlanivimab (Part 2-Prevention)","type":"EXPERIMENTAL","interventionNames":["Drug: Bamlanivimab"]},{"label":"Bamlanivimab + Etesevimab (Part 2-Prevention)","type":"EXPERIMENTAL","interventionNames":["Drug: Bamlanivimab","Drug: Etesevimab"]},{"label":"Placebo Comparator: Placebo (Part 2-Prevention)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Bamlanivimab (Part 2 - Treatment)","type":"EXPERIMENTAL","interventionNames":["Drug: Bamlanivimab"]},{"label":"Bamlanivimab + Etesevimab (Part 2- Treatment)","type":"EXPERIMENTAL","interventionNames":["Drug: Bamlanivimab","Drug: Etesevimab"]},{"label":"Bamlanivimab (Part 3)","type":"EXPERIMENTAL","interventionNames":["Drug: Bamlanivimab"]},{"label":"Bamlanivimab + Etesevimab (Part 3)","type":"EXPERIMENTAL","interventionNames":["Drug: Bamlanivimab","Drug: Etesevimab"]}],"interventions":[{"name":"Bamlanivimab","otherNames":["LY-CoV555","LY3819253"]},{"name":"Placebo","otherNames":[]},{"name":"Etesevimab","otherNames":["LY-CoV016","LY3832479"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Part 1 and Part 2: Resident or facility staff in a skilled nursing or assisted living facility with at least one confirmed case of SARS-CoV-2 detection less than or equal to (≤)7 days prior to randomization\n* Are men or non-pregnant women who agree to contraceptive requirements\n* Agree to the collection of nasal, mid-turbinate, oropharyngeal, and nasopharyngeal swabs, and venous blood as specified in the schedule of activities\n* Have venous access sufficient to allow intravenous infusions and blood sampling\n* The participant or legally authorized representative give signed informed consent\n* Part 3 only: Resident or staff in a skilled nursing or assisted living facility who satisfy at least one of the following at the time of screening\n\n  * Are greater than or equal to (≥) 65 years of age\n  * Have a body mass index (BMI) ≥ 35\n  * Have chronic kidney disease\n  * Have type 1 or type 2 diabetes\n  * Have immunosuppressive disease\n  * Are currently receiving immunosuppressive treatment, or\n  * Are ≥ 55 years of age AND have\n\n    * cardiovascular disease, OR\n    * hypertension, OR\n    * chronic obstructive pulmonary disease or other chronic respiratory disease\n* Positive SARS-CoV-2 test and infusion within 10 days of symptom onset, OR positive SARS-CoV-2 test and infusion within 10 days of testing if asymptomatic\n\nExclusion Criteria:\n\n* Parts 1 and 2:\n\n  * Recovered from confirmed COVID-19 disease or asymptomatic infection\n  * Prior history of a positive SARS-CoV-2 serology test\n  * History of convalescent COVID-19 plasma treatment\n  * Participation in a previous SARS-CoV-2 vaccine trial or received an approved SARS-CoV-2 vaccine\n  * Previous receipt of SAR-CoV-2-specific monoclonal antibodies\n* Have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With COVID-19","description":"The endpoint for the primary analysis is defined as the first occurrence of coronavirus disease - 2019 (COVID-19), defined as the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by reverse transcription - polymerase chain reaction (RT-PCR) AND mild or worse disease severity within 21 days of detection, by Day 57 (8 weeks after randomization). The participant needed to test positive on or prior to week 8, and they needed to develop their symptoms on or after their positive test date, but no later than 21 days after their positive swab OR Week 8, whichever comes first. Logistic regression model was used which includes occurrence of a primary endpoint event as the response variable, and treatment and stratification factors such as facility as explanatory variables.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":null},{"groupId":"OG001","value":"8.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Moderate or Worse Severity COVID-19","description":"The endpoint defined as the detection of SARS-CoV-2 by polymerase chain reaction (RT-PCR) AND moderate or worse disease severity within 21 days of detection, by Day 57 (Week 8) were summarized by treatment group. The participant needed to test positive on or prior to week 8, and they needed to develop their symptoms on or after their positive test date, but no later than 21 days after their positive swab OR Week 8, whichever comes first. Logistic regression model was used which includes occurrence of a primary endpoint event as the response variable, and treatment and stratification factors such as facility as explanatory variables.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","spread":null},{"groupId":"OG001","value":"8.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SARS-CoV-2","description":"Percentage of Participants with SARS-CoV-2.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","spread":null},{"groupId":"OG001","value":"17.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Are Hospitalized or Have Died Due to COVID-19","description":"Percentage of Participants Who are Hospitalized or Have Died due to COVID-19.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Experience COVID-19-Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death","description":"Percentage of Participants who Experience COVID-19-Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Die Due to COVID-19","description":"Percentage of Participants Who Die Due to COVID-19.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics (PK): Mean Concentration of Bamlanivimab Administered Alone","description":"Pharmacokinetics (PK): Mean Concentration of bamlanivimab Administered Alone.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"162","spread":"44.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.8","spread":"59.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.4","spread":"61.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":"46.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":"42.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":30,"n":587},"commonTop":["Urinary tract infection","Hypertension","Fall","Arthralgia","Back pain"]}}}